Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Oct 3;93(7):744-8.
doi: 10.1038/sj.bjc.6602783.

Side effects during chemotherapy predict tumour response in advanced colorectal cancer

B Schuell  1 , T Gruenberger, G V Kornek, N Dworan, D Depisch, F Lang, B Schneeweiss, W Scheithauer
Affiliations
Clinical Trial

Side effects during chemotherapy predict tumour response in advanced colorectal cancer

B Schuell et al. Br J Cancer. .

Abstract

To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial effect (I, n = 245), and the second with progressive disease (II, n = 58). Differences in terms of incidence rates, type and severity of ad verse events were analysed with univariate and multivariate models. The median number of side effects in group I was 6 vs 4 in group II (OR=1.342; P= 0.0001). An inverse correlation between disease control and treatment tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities (haematological: P = 0.0005 vs nonhaematological P = 0.0001). When median survival was analysed according to the number of adverse events, it was 10 (95% CI, 3-7), 16 (14-18), and 18 (16-20) months in case of 0-1, 2-5, and > or =6 adverse events, respectively (P = 0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median survival according to number of adverse events.
See this image and copyright information in PMC

References

    1. Ansfield FJ (1975) A randomized phase III study of four dosage regimens of 5-fluorouracil. Proc Am Assoc Cancer Res 16: 224 (abstract)
    1. Blum J, Jones S, Buzdar A (2001) Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: updated results and analyses of dose modification (abstract 693). Eur J Cancer 37(Suppl 6): S190 (abstract)
    1. Cascinu S, Del Ferro E, Catalano G (1996) Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 19: 371–374 - PubMed
    1. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with iv 5-fluorouracil/leucovorin. Ann Oncol 13: 566–575 - PubMed
    1. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R (1998) Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42: 336–340 - PubMed